Heider, Dominik http://orcid.org/0000-0002-3108-8311
Stetefeld, Henning http://orcid.org/0000-0002-8853-2145
Meisel, Andreas http://orcid.org/0000-0001-7233-5342
Bösel, Julian
Artho, Marie
Linker, Ralf
Angstwurm, Klemens
Neumann, Bernhard http://orcid.org/0000-0001-8254-8616
Neumann, Bernhard
Fuchs, Kornelius
Vidal, Amelie
De-Hyung, Lee
Kohler, Siegfried
Mergenthaler, Philipp
Brachaczek, Izabela
Maidhof, Jana
Wenke, Arno
Dohmen, Christian
Schönenberger, Silvia
Gerner, Stefan
Huttner, Hagen
Hagen, Manuel
Schneider, Hauke
Reichmann, Heinz
Rahmig, Jan
Schimmel, Eik
Niesen, Wolf
Fuhrerer, Hannah
Schneider-Gold, Christiane
Kleiter, Ingo
Fahrendorf, Christine
Thieme, Andrea
Steinbrecher, Andreas
Dunkel, Juliane
Roth, Christian
Alberty, Anke
Zinke, Jan
,
Funding for this research was provided by:
Universität Regensburg
Article History
Received: 5 December 2023
Revised: 16 January 2024
Accepted: 18 January 2024
First Online: 8 February 2024
Declarations
:
: Dominik Heider reports no disclosures; Henning R Stetefeld reports no disclosures; Andreas Meisel reports financial research support (paid to his institution) and personal fees from Alexion, AstraZeneca Rare Disease, financial research support (paid to his institution) and personal fees from argenx, personal fees from Grifols, personal fees from Hormosan, personal fees from Janssen, personal fees from Merck, personal fees from Novartis, financial research support (paid to his institution) from Octapharma, personal fees from UCB, outside the submitted work. He is chairman of the medical advisory board of the German Myasthenia Gravis Society; Julian Bösel reports personal fees from Medtronic, personal fees from Neuroptics, personal fees from TelaDoc, personal fees fomr PCORI and the DGNI outside the submitted work; Marie Artho reports no dicslosures; Ralf Linker reports no disclosures; Klemens Angstwurm reports travel support (until 2014) from Alexion, Bayer, BiogenIdec, MerckSerono, Novartis, Teva and honoria from Biogen und TEVA; moreover, he has been a principal investigator in studies in neuroimmunology sponsored by Alexion, Bayer, Biogen, Chugay, MerckSerono, Novartis, and Roche; all not related to the present study; Bernhard Neumann reports no disclosures. The authors declare no financial or other conflicts of interest related to the manuscript.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local ethic committees and institutional review boards of the participating centers approved the study based on the central vote of the ethics committee at University of Regensburg (No: 15-101-0259). Due to the retrospective character of the study, patient’s consent was not necessary according to the decisions of the ethic committees and institutional review boards.